X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ASTRAZENECA PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ASTRAZENECA PHARMA LUPIN LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x 20.1 102.9 19.5% View Chart
P/BV x 2.7 14.7 18.6% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 LUPIN LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
ASTRAZENECA PHARMA
Mar-14
LUPIN LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7501,285 136.2%   
Low Rs1,384634 218.2%   
Sales per share (Unadj.) Rs387.4189.6 204.3%  
Earnings per share (Unadj.) Rs56.6-0.2 -27,816.1%  
Cash flow per share (Unadj.) Rs76.83.8 1,998.6%  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs298.968.6 435.5%  
Shares outstanding (eoy) m451.5825.00 1,806.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.05.1 79.9%   
Avg P/E ratio x27.7-4,712.7 -0.6%  
P/CF ratio (eoy) x20.4249.6 8.2%  
Price / Book Value ratio x5.214.0 37.5%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m707,51323,988 2,949.5%   
No. of employees `00016.81.6 1,077.1%   
Total wages/salary Rs m28,4951,605 1,775.8%   
Avg. sales/employee Rs Th10,418.33,040.2 342.7%   
Avg. wages/employee Rs Th1,697.01,029.2 164.9%   
Avg. net profit/employee Rs Th1,523.0-3.3 -46,648.2%   
INCOME DATA
Net Sales Rs m174,9434,740 3,691.0%  
Other income Rs m1,06592 1,156.5%   
Total revenues Rs m176,0084,832 3,642.7%   
Gross profit Rs m44,931-130 -34,615.9%  
Depreciation Rs m9,122101 9,014.1%   
Interest Rs m1,5250-   
Profit before tax Rs m35,349-139 -25,449.2%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m9,7855 192,241.7%   
Profit after tax Rs m25,575-5 -502,447.9%  
Gross profit margin %25.7-2.7 -937.8%  
Effective tax rate %27.7-3.7 -755.4%   
Net profit margin %14.6-0.1 -13,612.7%  
BALANCE SHEET DATA
Current assets Rs m119,5422,726 4,384.6%   
Current liabilities Rs m61,2062,435 2,513.6%   
Net working cap to sales %33.36.1 542.4%  
Current ratio x2.01.1 174.4%  
Inventory Days Days7674 103.0%  
Debtors Days Days9041 220.5%  
Net fixed assets Rs m131,6601,035 12,717.1%   
Share capital Rs m90350 1,806.4%   
"Free" reserves Rs m134,073942 14,226.7%   
Net worth Rs m134,9761,716 7,865.7%   
Long term debt Rs m56,4780-   
Total assets Rs m266,0734,156 6,402.1%  
Interest coverage x24.2NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.71.1 57.7%   
Return on assets %10.2-0.1 -8,316.2%  
Return on equity %18.9-0.3 -6,387.8%  
Return on capital %19.30-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m81,885375 21,859.2%   
Fx outflow Rs m21,506470 4,574.3%   
Net fx Rs m60,378-96 -63,190.4%   
CASH FLOW
From Operations Rs m41,148-8 -507,993.8%  
From Investments Rs m-25,287-146 17,355.4%  
From Financial Activity Rs m4,332862 502.4%  
Net Cashflow Rs m20,193709 2,850.0%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 31.9 15.7 203.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 9.1 111.0%  
Shareholders   98,259 12,856 764.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Down Around 1%; Telecom & Metal Stocks Decline(01:30 pm)

Indian share markets are trading in the red presently. Sectoral indices are trading in the red with stocks in the telecom sector and metal sector witnessing maximum selling pressure.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 19, 2018 03:35 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS